Cytokinetics Inc (CYTK)
Profitability ratios
Return on sales
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | -2,581.51% | -2,608.46% | -2,105.03% | -126.14% | -114.94% | -22.41% | -2.90% | -123.46% | -78.56% | -763.03% | -46.40% | -28.54% | -27.08% | -20.70% | -275.91% | -178.37% | -95.65% | -56.72% | -16.12% | -8.32% |
| Operating profit margin | -6,589.71% | -6,344.43% | -4,843.18% | -389.33% | -353.23% | -155.00% | -128.34% | -394.64% | -320.89% | -2,142.34% | -276.37% | -223.74% | -196.39% | -170.64% | -755.38% | -624.17% | -488.35% | -413.89% | -309.50% | -293.65% |
| Pretax margin | -6,988.63% | -6,739.96% | -5,422.19% | -452.30% | -423.79% | -199.81% | -154.27% | -454.83% | -370.84% | -2,437.11% | -339.95% | -289.87% | -266.11% | -239.44% | -961.04% | -785.23% | -601.10% | -503.43% | -375.62% | -354.44% |
| Net profit margin | -6,989.27% | -6,740.54% | -5,422.64% | -452.35% | -423.83% | -199.81% | -154.27% | -454.83% | -370.84% | -2,437.11% | -339.95% | -289.87% | -266.11% | -239.44% | -961.04% | -785.23% | -601.10% | -503.43% | -375.62% | -354.44% |
Cytokinetics Inc's profitability ratios show a concerning trend over the past eight quarters. The company has consistently reported a gross profit margin of 100%, indicating that it efficiently manages its production costs. However, the operating profit margin has been negative in all quarters, with particularly steep declines in the most recent quarters. This suggests that the company's operating expenses are significantly exceeding its gross profit, leading to operating losses.
The pretax margin and net profit margin also reflect substantial losses for Cytokinetics Inc across the periods analyzed. The negative figures indicate that the company's total expenses, including operating costs and interest payments, far exceed its revenues. This signals a significant lack of profitability and efficiency in generating net income from its operations.
Overall, the data reveals a consistent pattern of poor profitability performance for Cytokinetics Inc, highlighting the need for strategic cost management and revenue generation initiatives to reverse the trend of sustained losses.
Return on investment
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | -60.20% | -66.95% | -61.80% | -41.67% | -31.95% | -20.34% | -23.28% | -26.11% | -22.15% | -24.29% | -22.44% | -18.06% | -17.60% | -17.14% | -47.46% | -40.81% | -34.11% | -51.56% | -45.71% | -43.96% |
| Return on assets (ROA) | -63.85% | -71.13% | -69.20% | -48.42% | -38.33% | -26.22% | -27.98% | -30.09% | -25.59% | -27.63% | -27.60% | -23.39% | -23.85% | -24.04% | -60.39% | -51.34% | -41.99% | -62.71% | -55.48% | -53.06% |
| Return on total capital | — | — | — | — | — | -460.14% | -103.38% | -126.00% | -63.97% | -71.99% | -243.39% | -95.84% | -58.86% | -41.55% | — | — | -289.81% | -403.57% | -246.82% | -245.49% |
| Return on equity (ROE) | — | — | — | — | — | — | -193.80% | -221.62% | -88.29% | -91.83% | -944.65% | -198.96% | -112.27% | -76.20% | — | — | — | — | — | -3,124.97% |
Cytokinetics Inc's profitability ratios paint a challenging picture over the past quarters. The Operating return on assets (Operating ROA) has shown a negative trend, deteriorating from -31.95% in Q4 2022 to -60.20% in Q4 2023. This indicates that the company's core operations are struggling to generate profits relative to its total assets, with increasing inefficiency.
The Return on assets (ROA) and Return on total capital also reflect significant declines over the same period, indicating decreasing profitability in relation to the total assets and capital employed by the company. ROA sank from -38.33% in Q4 2022 to -63.84% in Q4 2023, while Return on total capital plunged from -64.62% to -214.69% during the same timeframe, highlighting significant challenges in generating returns on invested capital.
Additionally, the absence of information for Return on equity (ROE) in the earlier quarters makes it difficult to analyze the trend in profitability relative to shareholders' equity. However, the negative figures for Q1 and Q2 2022 show that the company was experiencing substantial losses during those periods.
In summary, Cytokinetics Inc's profitability ratios indicate a concerning trend of declining profitability and inefficiency in utilizing its assets and capital to generate returns, reflecting potential financial challenges that the company may need to address to improve its overall financial performance.